MedUni Wien researcher of the month, Mai 2014
暂无分享,去创建一个
[1] M. Mayerhoefer,et al. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) , 2014, Annals of Hematology.
[2] M. Raderer,et al. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. , 2013, Blood.
[3] M. Raderer,et al. Ondansetron for diarrhea associated with neuroendocrine tumors. , 2013, The New England journal of medicine.
[4] W. Dolak,et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) , 2013, Haematologica.
[5] R. Greil,et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie , 2013, Haematologica.
[6] U. Jäger,et al. Subcutaneous dissemination pattern in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma , 2012, Haematologica.
[7] U. Jaeger,et al. Plasmacytic differentiation in MALT lymphomas following treatment with rituximab , 2012, Annals of Hematology.
[8] H. Agis,et al. Primary mucosa-associated lymphoid tissue (MALT) lymphoma of the liver: clinical, molecular, and microbiological aspects , 2012, Annals of Hematology.
[9] U. Jaeger,et al. Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis , 2011, Annals of Hematology.